


Director’s Report Appendix 4C Operational Report

The Company’s year to date unaudited Revenue to 30th September is up 51.7% year on year.



The Company’s closing cash balance stood at \$855k , up 35% on the same period the previous year, primarily a result of a Pro-Rata Rights Issue shortfall placement - 7th August 2023, resulting in additional \$300K equity Capital to the Group.

The Company has unused finance facilities totalling \$8.845 million at 30th September 2023.

Growth plans for the USA and in the Philippines is anticipated to begin in FY 2024, rewarding our FY 2003 investment, linked to the Hazavoid growth strategy and resources already deployed.

The September month Total Group Network Sales (including 100% of the 49% Winya associate) sales were collectively up 29% YOY for September whilst trading is L4L neutral overall for QTR 1.

The large investment in international sales staff, marketing, and operations in the USA and in The Philippines made in F23 has now yielded a significant lift in the Technology Pipeline. Open quotes are up to \$800K AUD in the USA from almost zero this time last year. Senior Management are currently in the USA working with larger clients to close off potential purchases and developing more rigid USA forecasts. Management continues to be hopeful that the overall USA strategy will yield a lift in earnings in the coming years utilising the Hazavoid Patent and the opportunities created with heightened risk and safety in the USA and other Global areas.

We have now received formal requests for tenders from the Metro Manila Development Association (Philippines) and a request for a trade delegation to attend product showings in Australia. The overall business development has shown good potential for future orders and we continue to develop and maintain a strategic focus in the Philippines region.

Opentec's client base in the upper ruggedised MILDEF market is expected to continue to grow and has secured large value PO's and confirmations of proposed orders to the value of \$7.4 Million in the early part of F24. This is expected to affect F25 Revenue.

The overall National Commercial Furniture Market has been quite subdued to September, however Inventis commercial Furniture Division has managed to continue to lift overall gross margins and to achieved DIFOT levels of 96% with Gregory Commercial Furniture.

Talks with GDK Group continue with a planned lease for the Furniture Division's manufacturing to move across to Victoria Street Wetherill Park NSW as part of part 1 of our staged plans. This will enable a close working relationship and allow a complete one-stop commercial offering to the Design and Construct Commercial and Office Market.

Technology will move to stand alone location near wholly owned ECD at Matraville. This will also allow a closer working relationship synergies.

The planned property moves (commencing late December 23), aims to reduce ongoing annual costs in the vicinity of \$500K pa.

The Company continues to align cost with expected trading conditions. We have dropped overall head count by 9.1% to date of this report and will continue to monitor overall costs. We will tender out Audit services subject to members approval (and expect costs savings there as well as other key areas.)

Gregory chairs, notably a leader in Ergonomics, is now certified to the highest level (160kg multi shift) of any chair by AFRDI. Our systems are also NDIS Certified assuring users of the optimum level of ergonomic, customised safety and infection control processes for our medical seating. Environmental Certification is to ISO14001. Gregory continues to gain ground in Ergonomic seating using technology with the G-Smart (smart phone app for iPhone and android.) The Company has also maintained ISO9001 and ISO14001 status across the Group and Green tick accreditation.


The Company has a proven track record of robust sustained double-digit sales growth over the last four-year period and internal forecasts are indicating robust sales subject to global economic conditions stabilising.

Exiting new product ranges were introduced. Healthcare range continued to feature in the Victorian Healthcare show, and additional work was completed on the new acoustic Pod. GCF supplied large orders into various hospitals in both NSW and Victoria and various initiatives are taking place to launch additional new products in F24.

The Company has a pipeline of potential M&A opportunities across both Divisions and the Group.

Phase 2 discussions continue with GDK Group.

STRATEGY VISION



Capital Management Plan

The Company expects to issue Shareholders with the AGM notices for the meeting date shortly.

The Notices outline various plans and structure moving forward to assist the company with its growth plans.

The Company continues to seek efficiency and synergy with its future plans.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Inventis Limited

ABN

40 084 068 673

Quarter ended ("current quarter")

30 September 2023

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	5,709	5,709
1.2 Payments for		
(a) research and development	(2)	(2)
(b) product manufacturing and operating costs	(2,624)	(2,624)
(c) advertising and marketing	(8)	(8)
(d) leased assets	(179)	(179)
(e) staff costs	(1,605)	(1,605)
(f) administration and corporate costs	(358)	(358)
1.3 Dividends received (see note 3)		
1.4 Interest received	1	1
1.5 Interest and other costs of finance paid	(469)	(469)
1.6 Income taxes paid	0	0
1.7 Government grants and tax incentives	13	13
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	478	478
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(4)	(4)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(4)	(4)

3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	300	300
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5 Proceeds from borrowings	2,650	2,650
3.6 Repayment of borrowings	(3,516)	(3,516)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	(566)	(566)

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	947	947
4.2 Net cash from / (used in) operating activities (item 1.9 above)	478	478
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(4)	(4)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	(566)	(566)
4.5 Effect of movement in exchange rates on cash held	-	-
4.6 Cash and cash equivalents at end of period	855	855

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	855	947
5.2 Call deposits		
5.3 Bank overdrafts		
5.4 Other (provide details)		
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	855	947

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1:	
	Interest on related party borrowings	373
	Directors' fees	62
	Total Payments	435
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
	<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>		
	<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1	Loan facilities	9,225	6,237
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)		
	Invoice Financing including purchase order financing	7,200	1,343
	Working Capital short term funding – 1	90	90
	Working Capital short term funding – 2	475	475
7.4	Total financing facilities	16,990	8,145
7.5	Unused financing facilities available at quarter end		8,845
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	Type	Security	Lender
	Loan	Secured	THN Credit Acceptance Pty Ltd
	Mortgage	Secured	THN Property Fund Pty Ltd
	Debtor Factoring	Secured	THN SPV1 Pty Ltd
	Purchase Funding	Secured	THN SPV1 Pty Ltd
	Working capital - 1	Unsecured	Starball Pty Ltd
	Working capital - 2	Secured	THN Property Fund Pty Ltd
		Interest Rate	Maturity Date
		10.00%	1 July 2025
		10.00%	1 July 2025
		10.42%	Ongoing
		10.42%	Ongoing
		9.50%	Ongoing
		15.67%	29/06/2024

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	478
8.2	Cash and cash equivalents at quarter end (item 4.6)	855
8.3	Unused finance facilities available at quarter end (item 7.5)	8,845
8.4	Total available funding (item 8.2 + item 8.3)	9,700
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	20.3

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?


Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 October 2023



Authorised by: Michael Green
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.